Old Web
English
Sign In
Acemap
>
authorDetail
>
Daniel Klunker
Daniel Klunker
Medicine
Methanosarcina mazei
Chemistry
Antibody
Catumaxomab
4
Papers
2
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Interim analysis of a phase I/II open label, dose-escalating study to investigate safety, tolerability, and preliminary efficacy of the trifunctional anti-HER2/neu x anti-CD3 antibody ertumaxomab in patients with HER2/neu expressing solid tumors progressing after standard therapy.
2014
Journal of Clinical Oncology
Nicole Haense
Claudia Pauligk
Frederik Marmé
Dominique Werner
Daniela Sorgius
Wael Hozaeel
Mohammad-Reza Rafiyan
Oliver G. Ottmann
Daniel Klunker
Michael Jäger
Elke Jäger
Horst Lindhofer
Salah-Eddin Al-Batran
Show All
Source
Cite
Save
Citations (2)
Catumaxomab (Removab) – Trifunctional Antibodies: Combining Direct Tumor Cell Killing with Therapeutic Vaccination
2014
Horst Lindhofer
Michael Stanglmaier
Raymund Buhmann
Michael Jäger
Daniel Klunker
Peter Ruf
Juergen Hess
Show All
Source
Cite
Save
Citations (0)
Functional Characterization of group I and II chaperonins in the archaeon Methanosarcina mazei
2004
Angela Hirtreiter
Luís Figueiredo
Daniel Klunker
Bernd Haas
Debbie Ang
Dean Naylor
Michael J. Kerner
Costa Georgopoulos
Ulrich Hartl
Manajit Hayer-Hartl
Show All
Source
Cite
Save
Citations (0)
Chaperon-vermittelte Proteinfaltung in Archaea
2003
Daniel Klunker
Show All
Source
Cite
Save
Citations (0)
1